Document Detail


Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
MedLine Citation:
PMID:  21047224     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.
METHODS: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study. The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months. We gave everolimus orally, at a dose of 3.0 mg per square meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter.
RESULTS: We enrolled 28 patients. Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%). Marked reductions were seen within 3 months and were sustained. There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma. Of the 16 patients for whom 24-hour video electroencephalography data were available, seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02). The mean (±SD) score on the validated Quality-of-Life in Childhood Epilepsy questionnaire (on which scores can range from 0 to 100, with higher scores indicating a better quality of life) was improved at 3 months (63.4±12.4) and 6 months (62.1±14.2) over the baseline score (57.8±14.0). Single cases of grade 3 treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia were reported.
CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).
Authors:
Darcy A Krueger; Marguerite M Care; Katherine Holland; Karen Agricola; Cynthia Tudor; Prajakta Mangeshkar; Kimberly A Wilson; Anna Byars; Tarek Sahmoud; David Neal Franz
Related Documents :
16340384 - Efficacy of levetiracetam in huntington disease.
16806994 - Acth therapy for generalized seizures other than spasms.
17653494 - Long-term changes in adas-cog: what is clinically relevant for disease modifying trials...
9305334 - Gabapentin monotherapy: i. an 8-day, double-blind, dose-controlled, multicenter study i...
23478104 - Evaluating the hatch score for predicting progression to sustained atrial fibrillation ...
23338114 - Prospective analysis of 44 consecutive liver transplants performed at a university hosp...
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The New England journal of medicine     Volume:  363     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-04     Completed Date:  2010-11-12     Revised Date:  2013-08-22    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1801-11     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatrics, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00411619
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Adult
Angiofibroma / drug therapy
Anticonvulsants / therapeutic use
Astrocytoma / drug therapy*,  etiology,  pathology
Brain Neoplasms / drug therapy*,  etiology,  pathology
Child
Child, Preschool
Cognition / drug effects
Drug Therapy, Combination
Facial Neoplasms / drug therapy
Female
Humans
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
Male
Prospective Studies
Protein-Serine-Threonine Kinases / antagonists & inhibitors*
Quality of Life
Seizures / drug therapy*,  etiology
Sirolimus / administration & dosage,  adverse effects,  analogs & derivatives*,  pharmacokinetics
TOR Serine-Threonine Kinases
Tuberous Sclerosis / complications,  drug therapy*
Young Adult
Grant Support
ID/Acronym/Agency:
UL1 TR000077/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Intracellular Signaling Peptides and Proteins; 159351-69-6/everolimus; 53123-88-9/Sirolimus; EC 2.7.1.1/MTOR protein, human; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 2.7.11.1/Protein-Serine-Threonine Kinases
Comments/Corrections
Comment In:
N Engl J Med. 2011 Feb 10;364(6):577   [PMID:  21306252 ]
N Engl J Med. 2011 Feb 10;364(6):576-7; author reply 577   [PMID:  21306253 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety of recombinant activated factor VII in randomized clinical trials.
Next Document:  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.